Summary

The global Life science analytics market is projected to reach USD 61.94 billion by 2029 from USD 35.69 billion in 2024, at a CAGR of 11.7% during the forecast period. The market is expected to grow as a result of the heterogenity & complexity of big data in life sciences, surging demand for technologically advanced analytical solutions for various applications across the industry, such as, research & development, commercialization (market access, pricing, sales & marketing, etc), safety, among others. Moreover, the market has experienced growth due to the need for improved data standardization across the life science & healthcare industry. However, insufficient IT infrastructure, and reluctance towards adoption of analytics solutions in emerging economies are some of the factors that are expected to pose a challenge to the market growth.

“Software-as-a-service (SaaS) subsegment, under the life science analytics software segment is expected to register highest growth during the forecast period.”
The life science analytics software segment is sub-segmented into on-premise, cloud-based, and software-as-a-service. In 2023, the software-as-a-service (SaaS) segment is expected to register the highest growth during the forecast period. The growth of the SaaS segment is attributed to the ample number of advantages offered by this model, such as the seamless integration of data from various cloud silos, unlimited user access from remote locations, low maintenance costs, high security, privacy, easy accessibility, no upfront capital investment for hardware, and extreme capacity flexibility and optimized resource utilization. Moreover, several applications offered by the SaaS model, spanning areas such as accounting, performance monitoring, and communication through webmail and instant messengers, further contribute to the segment's growth.

“Pharmaceutical & Biotechnology companies is projected to dominate the market in the life science analytics market, by end user during the forecast period.”
The pharmaceutical & biotechnology companies, medical device companies, research institutes, and outsourced life science organizations such as CROS, CMOs, independent contractors, etc., make up the end user segments of the life science analytics market. In 2023, the pharmaceutical & biotechnology companies accounted for a significant share of the life science analytics market, by end user. The segment is also expected to register paramount growth during the forecast period. The prominent position & high growth of this segment is due to the increasing R&D expenditure of pharma & biotech companies, the increasing use of analytics for research & development processes, pharma sales and marketing, growing importance of analytics in pharmacovigilance, the need to accelerate drug discovery, optimize clinical trials, and enhance regulatory compliance through data-driven insights. Moreover, the push for personalized medicine and precision therapeutics, The integration of Al and machine learning further strengthens the value of analytics in the pharma & biotech industry.

“Asia Pacific is expected to register highest market growth during the forecast period.”
The life science analytics market is bifurcated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific region is expected to register highest growth during the forecast period. The high growth of this region is attributed to the the presence of a large and growing patient population in the region, the increasing need for innovative therapies, the emergence of big data in healthcare, increasing spending on HCIT infrastructure, and the shifting focus of various market players on emerging countries in the region. Government initiatives to promote the adoption of digital & technologically enabled solutions across life science industry, and significant focus on integrating sophisticated technologies across the workflows also contributes to the growth.

The break-down of primary participants is as mentioned below:
• By Company Type - Tier 1: 32%, Tier 2: 44%, and Tier 3: 24%
• By Designation - Directors: 30%, Manager: 34%, and Others: 36%
• By Region - North America: 40%, Europe: 28%, Asia Pacific: 20%, Latin America: 7% and Middle East & Africa: 5%

List of Companies Profiled in the Report
o Oracle (US)
o Merative (formerly IBM) (US)
o SAS Institute (US)
o Accenture (Ireland)
o IQVIA (US)
o Cognizant (US)
o Wipro (India)
o Veradigm (US)
o Optum (US)
o Microsoft (US)
o MaxisIT (US)
o ExlService Holdings (US)
o Inovalon (US)
o CitiusTech (US)
o Saama (US)
o Axtria (US)
o Clarivate (UK)
o ThoughtSphere (US)
o ThoughtSpot (US)
o Salesforce (US)
o Google LLC (US)
o Amazon Web Services, Inc. (US)
o Veeva Systems (US)
o Elsevier (Netherlands)
o Komodo Health, Inc. (US)
Research Coverage:
The report analyzes the Life science analytics market and aims to estimate the market size and future growth potential of various market segments, based on type, component, applicarion, end user, and region. The report also analyses factors (such as drivers, opportunities and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total life science analytics market. The report forecasts the revenue of the market segments with respect to five major regions. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
• Analysis of key drivers (rising pressure to curb healthcare spending, need for improved data standardization, technological advancements in analytical solutions, heterogeneity and complexity of big data in life sciences, growing adoption of analytical solutions in clinical trials, increasing R&D expenditure in pharmaceutical & biotechnology companies), restraints (high implementation costs of advanced analytical solutions, data privacy concerns), opportunities (growing focus on value-based care, use of analytics in precision & personalized medicine, big data analytics for R&D productivity, growing adoption of cloud-based analytics), challenges (issues associated with data integration, shortage of skilled personnel, reluctance to adopt life science analytics solutions in emerging countries) are factors contributing the growth of the life science analytics market.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the life science analytics market.
• Market Development: Comprehensive information on the lucrative emerging markets, type of solution, component, deployment model, industry, and region.
• Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, investments in the life science analytics market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global life science analytics market such as Oracle (US), Merative (formerly IBM) (US), SAS Institute (US), Accenture (Ireland), IQVIA (US), Cognizant (US), Wipro (India), Veradigm (US), Optum (US).

ページTOPに戻る

Table of Contents

1 INTRODUCTION 36
1.1 STUDY OBJECTIVES 36
1.2 MARKET DEFINITION 36
1.3 MARKET SCOPE 37
1.3.1 MARKETS COVERED 37
1.3.2 INCLUSIONS & EXCLUSIONS 38
1.3.3 YEARS CONSIDERED 38
1.3.4 CURRENCY CONSIDERED 39
1.4 STAKEHOLDERS 39
1.5 SUMMARY OF CHANGES 40
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH DATA 41
2.1.1 SECONDARY DATA 42
2.1.1.1 Key data from secondary sources 43
2.1.2 PRIMARY DATA 43
2.1.2.1 Key industry insights 45
2.2 MARKET SIZE ESTIMATION 46
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 51
2.4 MARKET SHARE ESTIMATION 53
2.5 STUDY ASSUMPTIONS 53
2.6 LIMITATIONS 53
2.6.1 METHODOLOGY-RELATED LIMITATIONS 53
2.6.2 SCOPE-RELATED LIMITATIONS 53
2.7 RISK ASSESSMENT 54
3 EXECUTIVE SUMMARY 55
4 PREMIUM INSIGHTS 59
4.1 LIFE SCIENCE ANALYTICS MARKET OVERVIEW 59
4.2 LIFE SCIENCE ANALYTICS MARKET, BY REGION 60
4.3 NORTH AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY END USER & REGION 60
4.4 LIFE SCIENCE ANALYTICS MARKET: GEOGRAPHIC SNAPSHOT 61
4.5 LIFE SCIENCE ANALYTICS MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES 61
 
5 MARKET OVERVIEW 62
5.1 INTRODUCTION 62
5.2 MARKET DYNAMICS 62
5.2.1 DRIVERS 63
5.2.1.1 Rising pressure to curb healthcare spending 63
5.2.1.2 Need for improved data standardization 63
5.2.1.3 Technological advancements in analytical solutions 64
5.2.1.4 Heterogeneity and complexity of big data in life sciences 65
5.2.1.5 Growing adoption of analytical solutions in clinical trials 65
5.2.1.6 Increasing R&D expenditure in pharmaceutical &
biotechnology companies 66
5.2.2 RESTRAINTS 67
5.2.2.1 High implementation costs of advanced analytical solutions 67
5.2.2.2 Data privacy concerns 67
5.2.3 OPPORTUNITIES 69
5.2.3.1 Growing focus on value-based care 69
5.2.3.2 Use of analytics in precision & personalized medicine 69
5.2.3.3 Big data analytics for R&D productivity 70
5.2.3.4 Growing adoption of cloud-based analytics 71
5.2.4 CHALLENGES 71
5.2.4.1 Issues associated with data integration 71
5.2.4.2 Shortage of skilled personnel 72
5.2.4.3 Reluctance to adopt life science analytics solutions in
emerging countries 72
5.3 INDUSTRY TRENDS 73
5.3.1 GROWING ADOPTION OF ANALYTICS IN COMMERCIAL OPERATIONS 73
5.3.2 LEVERAGING DATA & ANALYTICS TO ACCELERATE DRUG
DISCOVERY & DEVELOPMENT 74
5.3.3 FOCUS ON REAL-TIME DATA ANALYTICS 74
5.4 TECHNOLOGY ANALYSIS 75
5.4.1 KEY TECHNOLOGIES 75
5.4.1.1 Artificial intelligence and machine learning 75
5.4.1.2 Big data analytics 75
5.4.1.3 Quantum computing 76
5.4.2 COMPLEMENTARY TECHNOLOGIES 76
5.4.2.1 Bioinformatics tools 76
5.4.2.2 Internet of things 76
5.4.3 ADJACENT TECHNOLOGIES 77
5.4.3.1 Blockchain 77
5.5 ECOSYSTEM ANALYSIS 77
5.6 VALUE CHAIN ANALYSIS 79
 
5.7 PORTER’S FIVE FORCES ANALYSIS 81
5.7.1 THREAT OF NEW ENTRANTS 82
5.7.2 THREAT OF SUBSTITUTES 82
5.7.3 BARGAINING POWER OF SUPPLIERS 82
5.7.4 BARGAINING POWER OF BUYERS 82
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 83
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA 83
5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS 83
5.8.2 BUYING CRITERIA 84
5.9 CASE STUDY ANALYSIS 85
5.9.1 NOVARTIS USES MULTI-CLOUD DATA ANALYTICS PLATFORM TO OPTIMIZE OPERATIONS AND ACCELERATE INNOVATION 85
5.9.2 SAS VISUAL ANALYTICS HELPS MAXIMIZE PROFITABILITY THROUGH PRESCRIPTIVE ANALYTICS & DATA VISUALIZATION 86
5.9.3 STREAMLINING REGULATORY MONITORING AND IMPACT ASSESSMENTS: GEDEON RICHTER’S PARTNERSHIP WITH CLARIVATE 87
5.10 REGULATORY LANDSCAPE 88
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 88
5.10.2 NORTH AMERICA 90
5.10.3 EUROPE 91
5.10.4 ASIA PACIFIC 91
5.10.5 MIDDLE EAST & AFRICA 92
5.10.6 LATIN AMERICA 92
5.11 PRICING ANALYSIS 93
5.11.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY APPLICATION 94
5.11.2 AVERAGE SELLING PRICE, BY REGION 94
5.12 KEY CONFERENCES AND EVENTS, 2024–2025 95
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 96
5.14 PATENT ANALYSIS 96
5.14.1 PATENT PUBLICATION TRENDS 96
5.14.2 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES 97
5.14.3 MAJOR PATENTS 98
5.15 END-USER ANALYSIS 99
5.15.1 UNMET NEEDS 99
5.15.2 END-USER EXPECTATIONS 101
5.16 LIFE SCIENCE ANALYTICS BUSINESS MODELS 102
5.16.1 SUBSCRIPTION-BASED MODEL 102
5.16.2 SAAS MODEL 102
5.16.3 PAY-PER-USE/USAGE-BASED MODEL 102
5.16.4 ENTERPRISE LICENSING 102
5.16.5 FREEMIUM MODEL 102
5.16.6 ENTERPRISE LICENSING 102
5.16.7 CONCURRENT LICENSING 103
5.16.8 CONSULTING SERVICES MODEL 103
5.16.9 PARTNERSHIP/REVENUE-SHARING MODEL 103
5.16.10 HYBRID MODELS 103
5.17 INVESTMENT & FUNDING SCENARIO 103
5.18 IMPACT OF AI/GENERATIVE AI ON LIFE SCIENCE ANALYTICS MARKET 106
5.18.1 TOP USE CASES & MARKET POTENTIAL 106
5.18.1.1 Key use cases 107
5.18.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION 109
5.18.2.1 Case Study 1: Knowledge Mining for a Global
Biopharmaceutical Company 109
5.18.2.2 Healthcare analytics market 110
5.18.3 USER READINESS AND IMPACT ASSESSMENT 111
5.18.3.1 User readiness 111
5.18.3.1.1 Pharmaceutical & biotechnology companies 111
5.18.3.1.2 Medical device companies 111
5.18.3.1.3 Research centers 111
5.18.3.1.4 Outsourced life science organizations 111
5.18.3.2 Impact assessment 112
5.18.3.2.1 User A: Pharmaceutical & biotechnology companies 112
5.18.3.2.1.1 Implementation 112
5.18.3.2.1.2 Impact 112
5.18.3.2.2 User B: Medical device companies 113
5.18.3.2.2.1 Implementation 113
5.18.3.2.2.2 Impact 113
5.18.3.2.3 User C: Research institutes 114
5.18.3.2.3.1 Implementation 114
5.18.3.2.3.2 Impact 114
5.18.3.2.4 User D: Outsourced life science organizations 115
5.18.3.2.4.1 Implementation 115
5.18.3.2.4.2 Impact 115
6 LIFE SCIENCE ANALYTICS MARKET, BY TYPE 116
6.1 INTRODUCTION 117
6.2 DESCRIPTIVE ANALYTICS 117
6.2.1 ADVANCED VISUAL DATA EXPLORATION AND SUPPORT FOR
INNOVATION TO DRIVE DEMAND 117
6.3 PREDICTIVE ANALYTICS 119
6.3.1 SIMULATION DEVELOPMENT FOR PREDICTING FUTURE TRENDS TO
PROPEL MARKET GROWTH 119
6.4 PRESCRIPTIVE ANALYTICS 120
6.4.1 REAL-TIME ANALYSIS FOR IMPROVED DECISION-MAKING TO
SUPPORT MARKET GROWTH 120
7 LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT 122
7.1 INTRODUCTION 123
7.2 SERVICES 123
7.2.1 MANAGED SERVICES 125
7.2.1.1 Analytical services 126
7.2.1.1.1 Focus on expediting approvals and product launches to drive growth 126
7.2.1.2 Consulting services 127
7.2.1.2.1 Support for R&D, process development, and other workflow processes to drive market 127
7.2.2 PROFESSIONAL SERVICES 128
7.2.2.1 Training & implementation 130
7.2.2.1.1 Stringent regulations, increasing competition, and need for skill development to propel demand 130
7.2.2.2 Maintenance & support services 131
7.2.2.2.1 Rising complexity of analytical technologies and expanding research needs to support market growth 131
7.2.2.3 Other professional services 132
7.3 SOFTWARE 133
7.3.1 ON-PREMISE SOLUTIONS 134
7.3.1.1 Provision of multivendor architecture and security benefits to
drive market 134
7.3.2 CLOUD-BASED SOLUTIONS 135
7.3.2.1 Real-time analysis and elimination of purchasing costs for software & hardware to drive adoption 135
7.3.3 SAAS-BASED SOLUTIONS 137
7.3.3.1 Increasing adoption of digital solutions and advantages of cloud-based models to drive growth 137
8 LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION 138
8.1 INTRODUCTION 139
8.2 RESEARCH & DEVELOPMENT 139
8.2.1 CLINICAL TRIALS 142
8.2.1.1 Life science analytics market for clinical trials, by type 143
8.2.1.1.1 Laboratory services 144
8.2.1.1.1.1 Better accuracy, efficiency, and data interpretation to support demand for lab services 144
8.2.1.1.2 Patient recruitment services 145
8.2.1.1.2.1 Need for better candidate identification and enrollment forecasting to propel market growth 145
8.2.1.1.3 Site identification services 146
8.2.1.1.3.1 Benefits in locating ideal trial sites and interpreting data to support adoption 146
8.2.1.1.4 Other clinical trial services 147
 
8.2.1.2 Life science analytics market for clinical trials, by phase 148
8.2.1.2.1 PHASE I 148
8.2.1.2.1.1 Strong pipeline of pharmaceutical companies to propel market growth 148
8.2.1.2.2 PHASE II 149
8.2.1.2.2.1 Extended duration of phase II studies to create growth opportunities for CROs 149
8.2.1.2.3 PHASE III 150
8.2.1.2.3.1 Rising trial expenditure to drive demand for cost-effective clinical research services 150
8.2.2 PRECLINICAL & DRUG DISCOVERY 151
8.2.2.1 Ability to assist researchers in process innovation and decision support to drive adoption 151
8.3 COMMERCIAL ANALYTICS 153
8.3.1 SALES & MARKETING SUPPORT 155
8.3.1.1 Rising analysis of digital marketing effectiveness to drive adoption 155
8.3.2 MARKET ACCESS 156
8.3.2.1 Focus on strategic pricing, reimbursement, and policy changes to support market growth 156
8.3.3 RWE & VALUE EVIDENCE 157
8.3.3.1 Increased data integration, partnerships, and technological to propel use of RWE 157
8.3.4 ENGAGEMENT SERVICES 158
8.3.4.1 Need for better patient engagement, digital advancements, and AI integration to propel market 158
8.4 REGULATORY COMPLIANCE 159
8.4.1 STRINGENT REQUIREMENTS FOR COMPLIANCE ADHERENCE
TO DRIVE ADOPTION 159
8.5 MANUFACTURING & SUPPLY CHAIN OPTIMIZATION 161
8.5.1 RISING NEED FOR REDUCING LOGISTICS COSTS TO
SUPPORT MARKET GROWTH 161
8.6 SAFETY 163
8.6.1 PHARMACOVIGILANCE 164
8.6.1.1 Monitoring of drug trials and medication programs to fuel
market uptake 164
8.6.2 MEDICAL DEVICE SAFETY 165
8.6.2.1 Stringent safety standards, rigorous risk assessments, and robust quality control to drive demand 165
8.6.3 DIAGNOSTIC VIGILANCE 166
8.6.3.1 Continuous monitoring, integration of diverse data sources, and ongoing education to enhance accuracy and thoroughness 166
 
9 LIFE SCIENCE ANALYTICS MARKET, BY END USER 168
9.1 INTRODUCTION 169
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 169
9.2.1 RISING NEED FOR INNOVATIVE THERAPIES TO DRIVE ANALYTICS USAGE IN PRODUCT DEVELOPMENT 169
9.3 MEDICAL DEVICE COMPANIES 171
9.3.1 ADOPTION OF DATA ANALYTICS FOR DEVICE COMMERCIALIZATION
TO DRIVE MARKET 171
9.4 RESEARCH CENTERS 172
9.4.1 NEED FOR ANALYZING LARGE VOLUMES OF DATA TO SUPPORT
MARKET GROWTH 172
9.5 OUTSOURCED LIFE SCIENCE ORGANIZATIONS 173
9.5.1 RISING R&D OUTSOURCING BY LIFE SCIENCE COMPANIES TO DRIVE MARKET 173
10 LIFE SCIENCE ANALYTICS MARKET, BY REGION 174
10.1 INTRODUCTION 175
10.2 NORTH AMERICA 175
10.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 176
10.2.2 US 182
10.2.2.1 Established economy and increasing R&D expenditure to drive adoption of analytical solutions 182
10.2.3 CANADA 187
10.2.3.1 Rising need for data standardization in life sciences to fuel uptake 187
10.3 EUROPE 192
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 192
10.3.2 GERMANY 197
10.3.2.1 Growing R&D investments by pharmaceutical & biotechnology companies to drive market 197
10.3.3 FRANCE 202
10.3.3.1 Growing government support for adoption of AI & big data analytics to drive market 202
10.3.4 UK 207
10.3.4.1 Rising clinical trial activity to drive uptake of life science
analytics solutions 207
10.3.5 ITALY 212
10.3.5.1 Growing number of drug approvals to drive uptake of
analytics solutions 212
10.3.6 SPAIN 216
10.3.6.1 Surging government investments focusing on personalized medicine to drive growth 216
10.3.7 REST OF EUROPE 221
 
10.4 ASIA PACIFIC 225
10.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 226
10.4.2 JAPAN 232
10.4.2.1 Growing government support for clinical R&D activities to
drive adoption 232
10.4.3 CHINA 237
10.4.3.1 Growth in life science industry to support adoption of solutions 237
10.4.4 INDIA 242
10.4.4.1 Rising R&D expenditure and drug development to support
market growth 242
10.4.5 REST OF ASIA PACIFIC 247
10.5 LATIN AMERICA 252
10.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 252
10.5.2 BRAZIL 257
10.5.2.1 Brazil to dominate life science analytics market in Latin America 257
10.5.3 MEXICO 262
10.5.3.1 Growing prominence of startups and rising R&D activity to
propel market 262
10.5.4 REST OF LATIN AMERICA 267
10.6 MIDDLE EAST & AFRICA 272
10.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 272
10.6.2 GCC COUNTRIES 278
10.6.2.1 Rising investments, advancements, and developing healthcare infrastructure to drive market 278
10.6.3 REST OF MIDDLE EAST & AFRICA 283
11 COMPETITIVE LANDSCAPE 288
11.1 OVERVIEW 288
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 288
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LIFE SCIENCE ANALYTICS MARKET 289
11.3 REVENUE ANALYSIS 290
11.4 MARKET SHARE ANALYSIS 291
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 292
11.5.1 STARS 293
11.5.2 EMERGING LEADERS 293
11.5.3 PERVASIVE PLAYERS 293
11.5.4 PARTICIPANTS 293
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 295
11.5.5.1 Company footprint 295
11.5.5.2 Type footprint 296
11.5.5.3 Application footprint 297
11.5.5.4 Component footprint 298
11.5.5.5 End-user footprint 299
11.5.5.6 Region footprint 300
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 301
11.6.1 PROGRESSIVE COMPANIES 301
11.6.2 RESPONSIVE COMPANIES 301
11.6.3 DYNAMIC COMPANIES 301
11.6.4 STARTING BLOCKS 301
11.6.5 COMPETITIVE BENCHMARKING 303
11.7 BRAND/SOFTWARE COMPARATIVE ANALYSIS 305
11.8 VALUATION & FINANCIAL METRICS 306
11.9 COMPETITIVE SCENARIO 307
11.9.1 PRODUCT LAUNCHES & APPROVALS 307
11.9.2 DEALS 308
12 COMPANY PROFILES 309
12.1 KEY PLAYERS 309
12.1.1 ORACLE 309
12.1.1.1 Business overview 309
12.1.1.2 Products & services offered 310
12.1.1.3 Recent developments 312
12.1.1.3.1 Deals 312
12.1.1.4 MnM view 312
12.1.1.4.1 Key strengths 312
12.1.1.4.2 Strategic choices 313
12.1.1.4.3 Weaknesses & competitive threats 313
12.1.2 MERATIVE 314
12.1.2.1 Business overview 314
12.1.2.2 Products & services offered 314
12.1.2.2.1 Deals 315
12.1.2.3 MnM view 315
12.1.2.3.1 Right to win 315
12.1.2.3.2 Strategic choices 315
12.1.2.3.3 Weaknesses & competitive threats 315
12.1.3 SAS INSTITUTE INC. 316
12.1.3.1 Business overview 316
12.1.3.2 Products & services offered 316
12.1.3.3 Recent developments 317
12.1.3.3.1 Product launches & approvals 317
12.1.3.3.2 Deals 317
12.1.3.4 MnM view 318
12.1.3.4.1 Right to win 318
12.1.3.4.2 Strategic choices 318
12.1.3.4.3 Weaknesses & competitive threats 318
12.1.4 ACCENTURE 319
12.1.4.1 Business overview 319
12.1.4.2 Products offered 321
12.1.4.3 Recent developments 321
12.1.4.3.1 Deals 321
12.1.4.4 MnM view 322
12.1.4.4.1 Right to win 322
12.1.4.4.2 Strategic choices 322
12.1.4.4.3 Weaknesses & competitive threats 322
12.1.5 IQVIA INC. 323
12.1.5.1 Business overview 323
12.1.5.2 Products & services offered 324
12.1.5.3 Recent developments 326
12.1.5.3.1 Product launches & approvals 326
12.1.5.3.2 Deals 326
12.1.5.3.3 Other developments 327
12.1.5.4 MnM view 327
12.1.5.4.1 Right to win 327
12.1.5.4.2 Strategic choices 327
12.1.5.4.3 Weaknesses & competitive threats 328
12.1.6 COGNIZANT 329
12.1.6.1 Business overview 329
12.1.6.2 Products & services offered 330
12.1.6.3 Recent developments 332
12.1.6.3.1 Product launches & approvals 332
12.1.6.3.2 Deals 332
12.1.7 WIPRO 333
12.1.7.1 Business overview 333
12.1.7.2 Products & services offered 334
12.1.7.3 Recent developments 336
12.1.7.3.1 Deals 336
12.1.8 VERADIGM LLC 337
12.1.8.1 Business overview 337
12.1.8.2 Products & services offered 338
12.1.8.3 Recent developments 339
12.1.8.3.1 Deals 339
12.1.9 OPTUM, INC. 340
12.1.9.1 Business overview 340
12.1.9.2 Products & services offered 341
12.1.9.3 Recent developments 341
12.1.9.3.1 Deals 341
 
12.1.10 MICROSOFT 342
12.1.10.1 Business overview 342
12.1.10.2 Products & services offered 343
12.1.10.3 Recent developments 344
12.1.10.3.1 Product & service launches & enhancements 344
12.1.10.3.2 Deals 344
12.1.11 MAXISIT 345
12.1.11.1 Business overview 345
12.1.11.2 Products & services offered 345
12.1.11.3 Recent developments 346
12.1.11.3.1 Product launches 346
12.1.11.3.2 Deals 346
12.1.12 EXLSERVICE HOLDINGS, INC. 347
12.1.12.1 Business overview 347
12.1.12.2 Products & services offered 348
12.1.12.3 Recent developments 349
12.1.12.3.1 Product launches 349
12.1.12.3.2 Deals 349
12.1.13 INOVALON 350
12.1.13.1 Business overview 350
12.1.13.2 Products & services offered 351
12.1.13.3 Recent developments 352
12.1.13.3.1 Product launches 352
12.1.13.3.2 Deals 352
12.1.14 CITIUSTECH INC. 353
12.1.14.1 Business overview 353
12.1.14.2 Products & services offered 353
12.1.14.3 Recent developments 354
12.1.14.3.1 Product launches 354
12.1.14.3.2 Deals 354
12.1.14.3.3 Expansions 355
12.1.15 SAAMA 356
12.1.15.1 Business overview 356
12.1.15.2 Products & services offered 356
12.1.15.3 Recent developments 357
12.1.15.3.1 Deals 357
12.1.16 AXTRIA 359
12.1.16.1 Business overview 359
12.1.16.2 Products & services offered 359
12.1.16.3 Recent developments 360
12.1.16.3.1 Product launches 360
12.1.16.3.2 Deals 360
12.1.16.3.3 Expansions 360
12.1.17 CLARIVATE 361
12.1.17.1 Business overview 361
12.1.17.2 Products & services offered 363
12.1.17.3 Recent developments 364
12.1.17.3.1 Product enhancements 364
12.1.17.3.2 Deals 364
12.1.18 THOUGHTSPHERE 365
12.1.18.1 Business overview 365
12.1.18.2 Products & services offered 366
12.1.18.3 Recent developments 366
12.1.18.3.1 Deals 366
12.1.19 THOUGHTSPOT INC. 367
12.1.19.1 Business overview 367
12.1.19.2 Products & services offered 367
12.1.19.3 Recent developments 368
12.1.19.3.1 Deals 368
12.1.19.3.2 Expansions 368
12.1.20 SALESFORCE, INC. 369
12.1.20.1 Business overview 369
12.1.20.2 Products & services offered 370
12.1.20.3 Recent developments 371
12.1.20.3.1 Deals 371
12.2 OTHER PLAYERS 372
12.2.1 GOOGLE LLC 372
12.2.2 AMAZON WEB SERVICES, INC. 373
12.2.3 VEEVA SYSTEMS 374
12.2.4 ELSEVIER 375
12.2.5 KOMODO HEALTH, INC. 376
13 APPENDIX 377
13.1 DISCUSSION GUIDE 377
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 382
13.3 CUSTOMIZATION OPTIONS 384
13.4 RELATED REPORTS 384
13.5 AUTHOR DETAILS 385